康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

603590 康辰药业

已收盘 04-30 15:00:00

{"stockData":{"symbol":"603590","market":"SH","secType":"STK","nameCN":"康辰药业","latestPrice":29.58,"timestamp":1714460400000,"preClose":29.84,"halted":0,"volume":1505700,"delay":0,"floatShares":158000000,"shares":160000000,"eps":1.0403,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.26,"latestTime":"04-30 15:00:00","open":29.79,"high":29.88,"low":29.46,"amount":44627400,"amplitude":0.0141,"askPrice":29.58,"askSize":6,"bidPrice":29.57,"bidSize":16,"shortable":0,"etf":0,"ttmEps":1.0403,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"adjPreClose":29.84,"symbolType":"stock","openAndCloseTimeList":[[1714440600000,1714447800000],[1714453200000,1714460400000]],"highLimit":32.82,"lowLimit":26.86,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":160000000,"pbRate":1.5,"roa":"--","roe":"1.34%","epsLYR":0.96,"committee":0.242424,"marketValue":4733000000,"floatMarketCap":4659000000,"peRate":28.434105,"changeRate":-0.0087,"turnoverRate":0.0096,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-05-06。"},"requestUrl":"/m/hq/s/603590/wiki","defaultTab":"wiki","newsList":[{"id":"2431347201","title":"中航证券：给予康辰药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431347201","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431347201?lang=zh_cn&edition=full","pubTime":"2024-04-30 20:52","pubTimestamp":1714481533,"startTime":"0","endTime":"0","summary":"中航证券有限公司李蔚近期对康辰药业进行研究并发布了研究报告《核心产品持续放量，研发项目顺利推进》，本报告对康辰药业给出买入评级，当前股价为29.58元。公司目前主要的在研项目包括KC1036、金草片和犬用注射用尖吻蝮蛇血凝酶。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000050025.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431734405","title":"康辰药业获中航证券买入评级，核心产品持续放量，研发项目顺利推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2431734405","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431734405?lang=zh_cn&edition=full","pubTime":"2024-04-30 20:44","pubTimestamp":1714481062,"startTime":"0","endTime":"0","summary":"4月30日，康辰药业获中航证券买入评级，近一个月康辰药业获得6份研报关注。研报认为，康辰药业作为我国血凝酶制剂行业细分领域龙头企业，受益于医疗机构手术人次恢复增长，通过持续的研发创新和产品引入丰富产品管线，目前各项研发项目顺利推进，创新中药金草片Ⅲ期临床试验达到研究终点，KC1036治疗晚期食管鳞癌即将进入临床Ⅲ期阶段，青少年尤文肉瘤适应症获批临床，未来公司有望迎来创新成果的多样化兑现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043020442787c3cb85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043020442787c3cb85&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431336312","title":"康辰药业获西南证券买入评级，苏灵销量快速增长，创新管线持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2431336312","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431336312?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:44","pubTimestamp":1714448695,"startTime":"0","endTime":"0","summary":"4月30日，康辰药业获西南证券买入评级，近一个月康辰药业获得5份研报关注。研报预计2024-2026年归母净利润分别为1.9亿元、2.3亿元和2.9亿元。研报认为，随着公司苏灵等存量产品快速增长，多措并举完善创新体系布局，KC1036已展现优异临床疗效。风险提示：市场竞争风险、药品价格下行风险、新药研发风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301145038b648c68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301145038b648c68&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431380640","title":"西南证券：给予康辰药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431380640","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431380640?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:17","pubTimestamp":1714447042,"startTime":"0","endTime":"0","summary":"西南证券股份有限公司杜向阳近期对康辰药业进行研究并发布了研究报告《2023年报点评：苏灵销量快速增长，创新管线持续推进》，本报告对康辰药业给出买入评级，当前股价为29.56元。　　苏灵医保解限销量快速增长，密盖息完成业绩承诺。随着公司苏灵等存量产品快速增长，多措并举完善创新体系布局，KC1036已展现优异临床疗效，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000024292.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431357448","title":"康辰药业获中银证券买入评级，利润端表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2431357448","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431357448?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:14","pubTimestamp":1714385665,"startTime":"0","endTime":"0","summary":"4月29日，康辰药业获中银证券买入评级，近一个月康辰药业获得4份研报关注。研报预计公司2023年实现营业收入9.20亿元，同比增加6.15%，归母净利润1.50亿元，同比增加48.24%。2024年第一季度公司营业收入1.99亿元，同比增加20.67%，归母净利润0.42亿元，同比增加62.28%。中银证券指出，公司主力产品“苏灵”市场份额增长，新药研发项目积极推进，预计这些因素将成为公司新的发展动力。风险提示：市场竞争加剧风险、新药研发进度不及预期风险、医药行业政策风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291814318b618bf7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291814318b618bf7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431802698","title":"中银证券：给予康辰药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431802698","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431802698?lang=zh_cn&edition=full","pubTime":"2024-04-29 17:52","pubTimestamp":1714384347,"startTime":"0","endTime":"0","summary":"中银国际证券股份有限公司刘恩阳,薛源近期对康辰药业进行研究并发布了研究报告《利润端表现亮眼，创新成果落地顺利推进》，本报告对康辰药业给出买入评级，当前股价为29.84元。“苏灵”获医保解限和顺利通过医保续约后，市场准入优势进一步扩大，提升“苏灵”的市场份额及优势，实现较快放量，2023年苏灵销量同比增加19.83%。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900023593.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431295025","title":"太平洋：给予康辰药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431295025","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431295025?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:50","pubTimestamp":1714359038,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司谭紫媚,张懿近期对康辰药业进行研究并发布了研究报告《康辰药业：苏灵放量助力业绩增长，重点创新药管线推进顺利》，本报告对康辰药业给出买入评级，当前股价为30.0元。根据统计分析结果表明，金草片在为期12周治疗期内VAS评分的疼痛消失率达到主要研究终点，金草片的安全性和耐受性良好，不良事件发生率低。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900007344.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430813850","title":"康辰药业2023年营收9.2亿净利1.5亿 董事长刘建华薪酬60.49万","url":"https://stock-news.laohu8.com/highlight/detail?id=2430813850","media":"挖贝网","top":-1,"share":"https://www.laohu8.com/m/news/2430813850?lang=zh_cn&edition=full","pubTime":"2024-04-28 14:40","pubTimestamp":1714286447,"startTime":"0","endTime":"0","summary":"挖贝网4月28日，康辰药业近日发布2023年年度报告，报告期内公司实现营业收入920,011,779.75元，同比增长6.15%；归属于上市公司股东的净利润150,450,744.29元，同比增长48.24%。本报告期公司营业收入92,001.18万元，比上年同期增长6.15%；归属于母公司所有者的净利润15,045.07万元，比上年同期增长48.24%；归属于母公司所有者的扣除非经常性损益的净利润为12,693.54万元，比上年同期增长42.51%。公告显示，报告期内董事、监事、高级管理人员报酬合计821.58万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042814421687b9bcc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042814421687b9bcc6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430228162","title":"康辰药业获平安证券买入评级，23年成本端改善明显，2024下半年KC1036迎重要节点","url":"https://stock-news.laohu8.com/highlight/detail?id=2430228162","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430228162?lang=zh_cn&edition=full","pubTime":"2024-04-26 18:44","pubTimestamp":1714128267,"startTime":"0","endTime":"0","summary":"4月26日，康辰药业获平安证券买入评级，近一个月康辰药业获得2份研报关注。公司研发进展顺利，KC1036进入临床3期。KC1036是公司核心在研项目，公司实行单药多适应症并行和联合用药方案并行的研发策略。目前公司正加快推进KC1036治疗晚期食管鳞癌3期临床研究。研报正预测康辰药业于2023年成本端改善，所得税费用同比大幅减少，以及2024下半年KC1036迎来的重要节点，所以给出了推荐的评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261844288b56dfa4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261844288b56dfa4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430210382","title":"平安证券：给予康辰药业增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2430210382","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430210382?lang=zh_cn&edition=full","pubTime":"2024-04-26 18:31","pubTimestamp":1714127476,"startTime":"0","endTime":"0","summary":"平安证券股份有限公司叶寅,韩盟盟近期对康辰药业进行研究并发布了研究报告《23年成本端改善明显，2024下半年KC1036迎重要节点》，本报告对康辰药业给出增持评级，当前股价为29.48元。　　平安观点：　　2023年成本端改善明显，所得税费用同比大幅减少。　　看好KC1036BIC潜力，叠加主业高增长，维持“推荐”评级。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600045817.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430285432","title":"康辰药业(603590)3月31日股东户数1.14万户，较上期增加4.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430285432","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430285432?lang=zh_cn&edition=full","pubTime":"2024-04-26 17:10","pubTimestamp":1714122642,"startTime":"0","endTime":"0","summary":"证券之星消息，近日康辰药业披露，截至2024年3月31日公司股东户数为1.14万户，较12月31日增加527.0户，增幅为4.85%。在生物制品行业个股中，康辰药业股东户数低于行业平均水平，截至3月31日，生物制品行业平均股东户数为3.36万户。从股价来看，2023年12月31日至2024年3月31日，康辰药业区间跌幅为17.8%，在此期间股东户数增加527.0户，增幅为4.85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261716568b568677&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261716568b568677&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430124713","title":"康辰药业将于5月16日召开股东大会，审议公司董事津贴等议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2430124713","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430124713?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:56","pubTimestamp":1714121812,"startTime":"0","endTime":"0","summary":"金融界4月26日消息，康辰药业发布公告，将于2024年5月16日召开年度股东大会，网络投票同日进行。股权登记日为5月10日，当日收市后持有康辰药业股票的投资者可以参与投票。会议地点：北京市昌平区中关村生命科学园科学园路7号院3号楼公司第三会议室。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042617042387b2d95a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042617042387b2d95a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430889258","title":"图解康辰药业一季报：第一季度单季净利润同比增62.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430889258","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430889258?lang=zh_cn&edition=full","pubTime":"2024-04-26 02:19","pubTimestamp":1714069148,"startTime":"0","endTime":"0","summary":"证券之星消息，康辰药业2024年一季报显示，公司主营收入1.99亿元，同比上升20.67%；归母净利润4165.43万元，同比上升62.28%；扣非净利润3965.67万元，同比上升74.63%；负债率11.27%，投资收益-53.69万元，财务费用-105.19万元，毛利率88.73%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600003209.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430232393","title":"图解康辰药业年报：第四季度单季净利润同比增183.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430232393","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430232393?lang=zh_cn&edition=full","pubTime":"2024-04-26 00:55","pubTimestamp":1714064135,"startTime":"0","endTime":"0","summary":"证券之星消息，康辰药业2023年年报显示，公司主营收入9.2亿元，同比上升6.15%；归母净利润1.5亿元，同比上升48.24%；扣非净利润1.27亿元，同比上升42.51%；其中2023年第四季度，公司单季度主营收入2.0亿元，同比下降28.26%；单季度归母净利润181.72万元，同比上升183.36%；单季度扣非净利润-1106.54万元，同比下降133.39%；负债率11.07%，投资收益556.12万元，财务费用-1145.93万元，毛利率89.02%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042601113687b01481&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042601113687b01481&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430239088","title":"康辰药业最新公告：2023年净利润同比增长48.24% 拟10派3元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430239088","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430239088?lang=zh_cn&edition=full","pubTime":"2024-04-26 00:31","pubTimestamp":1714062679,"startTime":"0","endTime":"0","summary":"康辰药业发布2023年年度报告，2023年，公司实现营业收入9.20亿元，比上年同期增长6.15%；归属于母公司所有者的净利润1.50亿元，比上年同期增长48.24%。拟向全体股东每10股派发现金股利人民币3.00元(含税)。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260033008b53bab6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260033008b53bab6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430800752","title":"康辰药业(603590.SH)发一季度业绩，净利润4165.43万元，同比增长62.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430800752","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2430800752?lang=zh_cn&edition=full","pubTime":"2024-04-25 23:16","pubTimestamp":1714058219,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康辰药业(603590.SH)发布2024年第一季度报告，报告期内公司实现营业收入1.99亿元，同比增长20.67%;归属于上市公司股东的净利润4165.43万元，同比增长62.28%;归属于上市公司股东扣除非经常性损益净利润3965.67万元，同比增长74.63%;基本每股收益0.27元/股。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1110901.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430235512","title":"康辰药业：2024年第一季度净利润约4165万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430235512","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430235512?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:23","pubTimestamp":1714055035,"startTime":"0","endTime":"0","summary":"康辰药业（SH 603590，收盘价：29.59元）4月25日晚间发布一季度业绩公告称，2024年第一季度营收约1.99亿元，同比增加20.67%；归属于上市公司股东的净利润约4165万元，同比增加62.28%；基本每股收益0.27元，同比增加68.75%。截至发稿，康辰药业市值为47亿元。文章来源：每日经济新闻原标题：康辰药业：2024年第一季度净利润约4165万元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042523410487afd906&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042523410487afd906&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430280504","title":"康辰药业：2023年度净利润约1.5亿元，同比增加48.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430280504","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430280504?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:15","pubTimestamp":1714054504,"startTime":"0","endTime":"0","summary":"每经AI快讯，康辰药业（SH 603590，收盘价：29.59元）4月25日晚间发布年度业绩报告称，2023年营业收入约9.2亿元，同比增加6.15%；归属于上市公司股东的净利润约1.5亿元，同比增加48.24%；基本每股收益0.96元，同比增加47.69%。截至发稿，康辰药业市值为47亿元。道达号（daoda1997）“个股趋势”提醒：1. 康辰药业近30日内北向资金持股量减少36.32万股，占流通股比例减少0.23%；2. 近30日内无机构对康辰药业进行调研。每经头条（nbdtoutiao）——罗永浩罕见没露面，这场重要直播近6小时才来9.3万人(记者 王瀚黎)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252302308b53808a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252302308b53808a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429117483","title":"康辰药业04月24日遭主力抛售137万元 环比增加470.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429117483","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429117483?lang=zh_cn&edition=full","pubTime":"2024-04-24 15:19","pubTimestamp":1713943172,"startTime":"0","endTime":"0","summary":"04月24日, 康辰药业股价涨1.00%，报收29.37元，成交金额3284万元，换手率0.72%，振幅1.99%，量比0.93。康辰药业今日主力资金净流出137万元，上一交易日主力净流出24万元，今日环比增加470.83%。|04月24日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|商络电子|5.31%|#|山水比德|5.25%|#|致尚科技|4.21%|#|广合科技|3.97%|#|辉煌科技|3.85%|#|世纪鼎利|3.59%|#|万丰奥威|3.50%|#|光洋股份|3.31%|#|吴通控股|3.27%|#|杰创智能|3.01%|康辰药业所在的生物制品行业，今日主力净流出1.40亿元，行业排名10/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042415350987a9abb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042415350987a9abb2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428553365","title":"康辰药业04月18日主力资金流入12万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2428553365","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428553365?lang=zh_cn&edition=full","pubTime":"2024-04-18 15:19","pubTimestamp":1713424775,"startTime":"0","endTime":"0","summary":"04月18日, 康辰药业股价跌0.76%，报收28.54元，成交金额3660万元，换手率0.81%，振幅2.99%，量比0.80。康辰药业今日主力资金净流入12万元，连续5日净流入，上一交易日主力净流入140万元，今日环比减少91.43%。该股近5个交易日下跌2.69%，主力资金累计净流入299万元；近20日主力资金累计净流出689万元，其中净流出天数为9日。该行业中净流入前三个股分别为上海莱士、华兰生物、西藏药业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418153358878eaa97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418153358878eaa97&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2018-08-27","address":"北京市密云区经济开发区兴盛南路11号","stockEarnings":[{"period":"1week","weight":0.0172},{"period":"1month","weight":-0.055},{"period":"3month","weight":0.0386},{"period":"6month","weight":-0.2448},{"period":"1year","weight":-0.1743},{"period":"ytd","weight":-0.2232}],"companyName":"北京康辰药业股份有限公司","boardCode":"AI0027","perCapita":"13836股","boardName":"医药制造业","registeredCapital":"16000万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":"　　北京康辰药业股份有限公司的主营业务是一家坚持以创新药研发为核心、以临床需求为导向，集研发、生产和销售于一体。目前公司产品和在研产品主要专注于血液、骨科以及肿瘤等市场空间较大的领域。公司主要产品“苏灵”是目前国内血凝酶制剂市场唯一的国家一类新药。","serverTime":1714655179867,"listedPrice":24.34,"stockholders":"11384人(较上一季度增加4.85%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康辰药业,603590,康辰药业股票,康辰药业股票老虎,康辰药业股票老虎国际,康辰药业行情,康辰药业股票行情,康辰药业股价,康辰药业股市,康辰药业股票价格,康辰药业股票交易,康辰药业股票购买,康辰药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}